Compare GSK plc (GSK) vs Palantir Technologies Inc (PLTR) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Palantir (PLTR) trades at $133.01, down 0.53% on the day, showing resilience near key support at $133 after recent volatility. The stock maintains a bullish technical trend with strong moving average signals, while fundamentals reveal explosive growth with 2025 revenue reaching $4.48 billion and net income surging to $1.63 billion. Recent partnerships with Nvidia and consistent earnings beats highlight ongoing business momentum, though valuation multiples remain elevated at 150x P/E and 66x P/S ratios.

The outlook remains positive given strong earnings trajectory and AI infrastructure demand, with analyst consensus target at $185.75 suggesting 40% upside potential. Primary risks include premium valuation sensitivity, competitive pressures in AI software, and execution challenges in sustaining high growth rates. Second quarter 2026 earnings on August 3 will be critical for validating current momentum.